Stifel Nicolaus Increases Cipher Pharmaceuticals (TSE:CPH) Price Target to C$17.00

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its target price increased by Stifel Nicolaus from C$16.00 to C$17.00 in a research report sent to investors on Wednesday, BayStreet.CA reports. They currently have a buy rating on the stock.

A number of other equities analysts have also issued reports on the company. Leede Financial lowered Cipher Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Friday, September 13th. Stifel Canada raised Cipher Pharmaceuticals from a hold rating to a strong-buy rating in a report on Monday, August 12th.

Cipher Pharmaceuticals Price Performance

Shares of CPH opened at C$14.53 on Wednesday. Cipher Pharmaceuticals has a one year low of C$4.10 and a one year high of C$19.69. The stock’s fifty day moving average is C$14.55 and its 200-day moving average is C$10.66. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.67 and a current ratio of 11.18. The firm has a market capitalization of C$371.82 million, a price-to-earnings ratio of 11.81 and a beta of 1.25.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last released its quarterly earnings results on Thursday, August 8th. The company reported C$0.16 EPS for the quarter, topping analysts’ consensus estimates of C$0.15 by C$0.01. The company had revenue of C$7.26 million for the quarter, compared to the consensus estimate of C$7.52 million. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. Equities analysts anticipate that Cipher Pharmaceuticals will post 1.4156977 EPS for the current year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.